← Back to headlines
Experts estimate this US biotech stock has 100 percent potential, one even 250 percent [premium]
Developers of medical active ingredients often have a long road ahead until a preparation is approved. This company has several in the pipeline.
7 Mar, 15:03 — 7 Mar, 16:35
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
Yahoo
Center
Right1
Right (1)
die-presse
Far R
Geographic diversity— 2 regions9/34
US1Austria1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
die-presse3h ago
Dieser US-Biotechaktie trauen Experten im Schnitt 100 Prozent Kurspotenzial zu, einer sogar 250 Prozent [premium]
Entwickler von medizinischen Wirkstoffen haben oft einen langen Weg vor sich, bis ein Präparat genehmigt ist. Bei diesem Unternehmen sind einige in der Pipeline. Insider haben kürzlich bei der Aktie zugekauft, und Experten sehen immenses Kurspotenzial.
Read full article →YahooMostly Factual1h ago
Where Will Eli Lilly Stock Be in 10 Years?
Read full article →Coverage Timeline
First report: die-presse · 7 Mar, 15:03|Full coverage: All 2 sources within 2h|Window: 2h
Left-leaningCenterRight-leaning
